Obalon Therapeutics Inc (OBLN) Stock Price & Overview
NASDAQ:OBLN
Current stock price
The current stock price of OBLN is 3.05 null. Today OBLN is down by -5.86%. In the past month the price increased by 29.24%. In the past year, price increased by 296.1%.
OBLN Key Statistics
- Market Cap
- 30.567M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.17
- Dividend Yield
- N/A
OBLN Stock Performance
OBLN Stock Chart
OBLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OBLN. When comparing the yearly performance of all stocks, OBLN is one of the better performing stocks in the market, outperforming 95.43% of all stocks.
OBLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBLN. Both the profitability and financial health of OBLN have multiple concerns.
OBLN Earnings
OBLN Forecast & Estimates
0 analysts have analysed OBLN and the average price target is 18.82 null. This implies a price increase of 517.02% is expected in the next year compared to the current price of 3.05.
For the next year, analysts expect an EPS growth of 43.12% and a revenue growth 953.33% for OBLN
OBLN Groups
Sector & Classification
OBLN Financial Highlights
Over the last trailing twelve months OBLN reported a non-GAAP Earnings per Share(EPS) of -3.17. The EPS increased by 76.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1391.09% | ||
| ROA | -64.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
OBLN Ownership
OBLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 15.19 | 165.895B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.83 | 162.696B | ||
| SYK | STRYKER CORP | 22.38 | 129.593B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.19 | 94.254B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.24 | 45.576B | ||
| IDXX | IDEXX LABORATORIES INC | 38.49 | 45.265B | ||
| BDX | BECTON DICKINSON AND CO | 11.34 | 44.083B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.17 | 33.4B | ||
| RMD | RESMED INC | 18.3 | 32.737B | ||
| DXCM | DEXCOM INC | 24.08 | 23.565B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.18 | 18.347B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 31.07 | 14.184B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OBLN
Company Profile
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company is headquartered in Carlsbad, California and currently employs 2 full-time employees. The company went IPO on 2016-10-06. The firm's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The firm has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Company Info
IPO: 2016-10-06
Obalon Therapeutics Inc
5421 Avenida Encinas Ste F
Carlsbad CALIFORNIA 92008 US
CEO: Andrew Rasdal
Employees: 2.0
Phone: 18584802400.0
Obalon Therapeutics Inc / OBLN FAQ
What does OBLN do?
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company is headquartered in Carlsbad, California and currently employs 2 full-time employees. The company went IPO on 2016-10-06. The firm's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The firm has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
What is the stock price of Obalon Therapeutics Inc today?
The current stock price of OBLN is 3.05 null. The price decreased by -5.86% in the last trading session.
Does OBLN stock pay dividends?
OBLN does not pay a dividend.
How is the ChartMill rating for Obalon Therapeutics Inc?
OBLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of Obalon Therapeutics Inc (OBLN)?
Obalon Therapeutics Inc (OBLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).
Can you provide the growth outlook for Obalon Therapeutics Inc?
The Revenue of Obalon Therapeutics Inc (OBLN) is expected to grow by 953.33% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.